GATC Health Announces Scientific Publication Highlighting Multiomics Approach to Drug Discovery

Irvine, CA – February 20, 2025 – GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, today announced the publication of a peer-reviewed research article in the American Journal of Biomedical Science & Research. The article, titled “Multiomics Experimental Design for Drug Discovery,” underscores the critical role of multiomics and systems biology in augmenting GATC Health's proprietary AI platform.

The publication, authored by GATC Health scientists Samuel Kho, Eric J. Mathur, Waldemar Lernhardt, Jayson Uffens, Ian Jenkins, and corresponding author Jonathan RT Lakey, emphasizes the limitations of single-omic approaches in addressing the complexities of drug discovery. While individual omics layers (genomics, transcriptomics, proteomics, and metabolomics) provide valuable insights, the study focuses on the necessity of integrating these diverse datasets to achieve a comprehensive understanding of biological systems.

From the article:

“By interweaving high-dimensional datasets, multiomics unearths actionable biomarkers and mechanistic insights that elude traditional methodologies. Such a holistic perspective has the potential to revolutionize early-stage drug discovery, refine clinical trial design with precision, and expedite the transition of innovative therapies from bench to bedside.”

The paper highlights high-level strategies for the successful application of multiomics in drug discovery—from target validation to drug repurposing. However, its successful application depends on meticulous experimental design, careful consideration of data dimensionality, and the use of appropriate analytical techniques detailed in the paper.

“Traditional single-omic studies often fall short in capturing the intricate interplay of molecular mechanisms that drive disease,” said Ian Jenkins, GATC’s Chief Science Officer. “GATC Health employs a systems biology approach to drug discovery by integrating multiomic datasets with advanced AI technologies. Research demonstrates that our approach offers a powerful framework for bridging the mechanistic gap and accelerating the identification of novel drug targets.”

Key Points from the Publication

• Multiomics offers a powerful framework to connect genotype to phenotype, while single-omics studies often only explain a small fraction of the variance in the data (the missing heritability problem).

• Multiomics uncovers actionable biomarkers and mechanistic insights that traditional methodologies may miss by combining diverse molecular layers (e.g., Genomics, Epigenomics, Transcriptomics, Proteomics, Metabolomics, Lipidomics).

• Multiomics can streamline target identification, reduce pre-clinical validation time, and improve the accuracy of drug efficacy and safety prediction by convincing stakeholders at all levels through a “comprehensive data package.”

• GATC Health employs a systems biology approach to drug discovery by integrating multiomic datasets with advanced AI technologies.

The paper details how multiomics data can enhance an AI platform's predictive capabilities, as evidenced in GATC’s Multiomics Advanced Technology™ (MAT) platform. By integrating multiomic data, the platform can generate more accurate in silico models of biological systems. This allows for the prediction of perturbations and the identification of potential therapeutic interventions with greater precision, ultimately leading to more effective treatments for patients.

About GATC Health

GATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.

For more information, visit www.gatchealth.com.